Back
C4 Therapeutics, Inc. 10K Form
Sell
34
CCCC
C4 Therapeutics, Inc.
Last Price:
$2.68
Seasonality Move:
-24.32%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
10K form not available
Receive CCCC News And Ratings
See the #1 stock for the next 7 days that we like better than CCCC
CCCC Financial Statistics
Sales & Book Value
| Annual Sales: | $35.6M |
|---|---|
| Cash Flow: | $-31.6M |
| Price / Cash Flow: | 0 |
| Annual Sales: | $2.08 |
| Price / Book: | 1.68 |
Profitability
| EPS (TTM): | -1.67100 |
|---|---|
| Net Income (TTM): | $-119.1M |
| Gross Margin: | $27.7M |
| Return on Equity: | -60.62% |
| Return on Assets: | -37.05% |
C4 Therapeutics, Inc. Earnings Forecast
Key C4 Therapeutics, Inc. Financial Ratios
-
The Gross Profit Margin over the past 4 years for CCCC is 77.82%.
-
The Selling, General & Administrative Expenses for CCCC have been equal to 118.38% of Gross Profit Margin.
-
The Research & Development expenses have been 310.92% of Revenue.
-
The Net Earning history of CCCC is -295.96% of Total Revenues.
-
Per Share Earnings over the last 7 years have been positive in 3 years.
C4 Therapeutics, Inc. Stock Price Chart
Industry, Sector and Symbol
| Stock Exchange: | NASDAQ |
|---|---|
| Industry: | Biotechnology |
| Sector: | Health Care |
| Current Symbol: | CCCC |
| CUSIP: | 12529R |
| Website: | c4therapeutics.com |
Debt
| Debt-to-Equity Ratio: | 0.4 |
|---|---|
| Current Ratio: | 5.76 |
| Quick Ratio: | 5.52 |
Price-to-Earnings
| Trailing P/E Ratio: | 0 |
|---|---|
| Forward P/E Ratio: | 0 |
CCCC Technical Analysis vs Fundamental Analysis
Sell
34
C4 Therapeutics, Inc. (CCCC)
is a Sell
Is C4 Therapeutics, Inc. a Buy or a Sell?
-
C4 Therapeutics, Inc. stock is rated a SellThe current C4 Therapeutics, Inc. [CCCC] share price is $2.67. The Score for CCCC is 34, which is 32% below its historic median score of 50, and infers higher risk than normal.